or Try an Advanced Search...

    Technical Analysis for AKBA - Akebia Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 1.34 0.75% 0.01
    AKBA closed up 0.75 percent on Friday, April 26, 2024, on 44 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 6
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical AKBA trend table...
    Date Alert Name Type % Chg
    200 DMA Support Bullish 0.00%
    Oversold Stochastic Weakness 0.00%
    200 DMA Support Bullish 0.75%
    NR7 Range Contraction 0.75%
    NR7-2 Range Contraction 0.75%
    Narrow Range Bar Range Contraction 0.75%
    Wide Bands Range Expansion 0.75%
    Oversold Stochastic Weakness 0.75%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.19%
    NR7 Range Contraction -2.19%
    Older End-of-Day Signals for AKBA ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 19 hours ago
    Up 1% about 19 hours ago
    200 DMA Support about 23 hours ago
    Fell Below Lower Bollinger Band about 23 hours ago
    Fell Below 200 DMA about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    AKBA Chart by TradingView
    Basic chart:

    Profile

    Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Kidney Disease Dialysis Anemia Chronic Kidney Disease Kidney Hypoxia Inducible Factors

    Is AKBA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 4 Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
    Apr 2 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Apr 2 Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
    Mar 28 FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
    Mar 28 Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
    Mar 28 Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
    Mar 28 Akebia stock jumps as FDA clears renal anemia therapy
    Mar 28 Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
    Mar 26 Akebia Awaits FDA Word On Second Crack At Vadadustat
    Mar 17 Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
    See more AKBA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.48
    52 Week Low 0.7801
    Average Volume 5,593,606
    200-Day Moving Average 1.32
    50-Day Moving Average 1.57
    20-Day Moving Average 1.45
    10-Day Moving Average 1.37
    Average True Range 0.12
    RSI (14) 37.89
    ADX 21.07
    +DI 15.34
    -DI 26.86
    Chandelier Exit (Long, 3 ATRs) 2.12
    Chandelier Exit (Short, 3 ATRs) 1.65
    Upper Bollinger Bands 1.63
    Lower Bollinger Band 1.27
    Percent B (%b) 0.19
    BandWidth 24.51
    MACD Line -0.09
    MACD Signal Line -0.07
    MACD Histogram -0.0129
    Fundamentals Value
    Market Cap 252.44 Million
    Num Shares 188 Million
    EPS -0.31
    Price-to-Earnings (P/E) Ratio -4.32
    Price-to-Sales 1.61
    Price-to-Book 4.12
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.43
    Resistance 3 (R3) 1.42 1.39 1.42
    Resistance 2 (R2) 1.39 1.36 1.39 1.41
    Resistance 1 (R1) 1.36 1.35 1.38 1.37 1.40
    Pivot Point 1.33 1.33 1.33 1.33 1.33
    Support 1 (S1) 1.30 1.30 1.32 1.31 1.28
    Support 2 (S2) 1.27 1.29 1.27 1.27
    Support 3 (S3) 1.24 1.27 1.27
    Support 4 (S4) 1.25